Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial - PubMed
3 hours ago
- #probiotics
- #metformin
- #HOMA-IR
- Multi-strain probiotic reduces gastrointestinal (GI) side effects in women with elevated HOMA-IR index treated with metformin.
- 12-week randomized controlled trial involving 30 women aged 25-45 with elevated HOMA-IR (≥2.5) but no diabetes diagnosis.
- Participants received either a multi-strain probiotic (2 × 10^9 CFU/day) or placebo alongside metformin (1000 mg/day).
- Probiotic group reported significantly fewer GI symptoms compared to placebo, including less abnormal stool consistency, frequency, and hard/lumpy stools.
- No significant differences in metabolic or anthropometric parameters between groups; improvements in fasting glucose, HOMA-IR, RBP4, and total cholesterol were attributed to metformin.
- Probiotic supplementation did not enhance metformin's metabolic efficacy but improved GI tolerability, potentially aiding adherence to therapy.
- Clinical trial registered under NCT06092060.